French digital radiography firm Biospace Med of Paris has raised $18 million to advance its market expansion in North America and Europe for its EOS ultralow-dose 2D/3D radiography system.
The company recently received clearance from the U.S. Food and Drug Administration (FDA) for EOS, which allows full-body 2D and 3D imaging of patients using less radiation dose than standard computed radiography x-ray.
Related Reading
FDA clears Biospace Med's sterEOS for pediatrics, March 11, 2010
Road to RSNA, Digital X-Ray, Biospace Med, October 22, 2008
FDA OKs 3D mode for Biospace Med's EOS, October 8, 2008
Biospace adds Latin American distributor, November 30, 2007
Biospace raises $18 million, November 27, 2007
Copyright © 2010 AuntMinnie.com